Clinical Trial: REFLEx Study

This study is no longer recruiting patients.

Sponsored by: Guidant Corporation
Information provided by: Guidant Corporation Identifier: NCT00146822


The REFLEx Study will evaluate if ENDOTAK RELIANCE G defibrillation leads with GORE ePTFE-covered coils are as good as or better than other comparative commercially available defibrillation leads with respect to electrical performance and termination efficacy in spontaneous tachyarrhythmic episodes.
Condition Intervention Phase
Phase IV

MedlinePlus related topics:  Arrhythmia

Study Type: Interventional
Study Design: Randomized, Single Blind, Active Control, Parallel Assignment

Official Title: ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance Study

Further Study Details: 
Primary Outcomes: Lead electrical properties; First shock conversion success rate for spontaneous fast ventricular tachycardia or ventricular fibrillation
Secondary Outcomes: Lead handling characteristics; Lead migration/dislodgment rates; Characterize the current ICD/CRT-D population; Effects of ischemia and revascularization and previous lead extraction on the lead’s electrical performance
Expected Total Enrollment:  1500

Study start: February 2004


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Inclusion Criteria:

• Patients who meet current ICD or CRT-D indications • Patients who are going to be implanted with one of the aforementioned ICD or CRT-D devices • Patients who are going to be implanted with active-fixation, dual-coil, endocardial defibrillation leads with compatible connectors (i.e., ENDOTAK RELIANCE G or study-comparative ICD leads) • Patients who sign and date a Patient Informed Consent form prior to device implant • Patients who remain in the clinical care of the enrolling physician in approved centers • Patients who are at least 18 years old

Exclusion Criteria:

• Patients who have a preexisting transvenous lead system that is not completely explanted • Patients who are hypersensitive to a single dose of approximately 1.0 mg of dexamethasone acetate • Patients who are expected to receive a heart transplant during the duration of the study • Patients whose estimated life expectancy is less than 12 months due to other medical conditions • Patients who currently have or who are likely to receive a tricuspid valve prosthesis • Patients who are likely to have an open-chest surgery in the next three months • Patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the REFLEx study.

• Patients who are mentally incompetent and cannot sign a Patient Informed Consent form or comply with the study • Patients who are pregnant

Location Information

Study chairs or principal investigators

Randolph Cooper, MD,  Principal Investigator,  Wake Heart Associates   

More Information

Study ID Numbers:  CR-CA-022504-L
Last Updated:  September 6, 2005
Record first received:  September 2, 2005 Identifier:  NCT00146822
Health Authority: United States: Institutional Review Board processed this record on 2005-09-13


  • Lead (Centers for Disease Control and Prevention)
  • Lead (Lab Tests Online)

Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us